Dr. Hikita is a co-founder and a member of the scientific advisory board of Kanjin Therapeutics. Dr. Hikita brings deep expertise in biochemistry, cell biology, and disease modeling to the company. His translational research experience with both rodent models and human samples guides our mission to develop innovative, life-improving medicines.

Dr. Hikita earned his Ph.D. from Nagoya University Graduate School of Medicine under the guidance of Prof. Kozo Kaibuchi, who found a RhoA/Rho-kinase mediated smooth muscle contraction. After his job as an Assistant Professor, Dr. Hikita joined Dr. Nakayama's research group in Max-Planck Institute for Heart and Lung Research in Germany, and co-invented the new therapeutic target to treat kidney disorders.